Montelukast Torrent Pharma (Uk)

Montelukast, the active ingredient in Montelukast Torrent Pharma, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. It is indicated for long‑term control of symptoms and is not intended for immediate relief of acute bronchospasm.

GNH USA supplies Montelukast Torrent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions.

Asthma: improves long‑term control of symptoms, decreases nighttime awakenings, and reduces the frequency and severity of asthma exacerbations in both adults and children. Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea caused by seasonal or perennial allergens, improving overall quality of life. Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity, allowing patients to maintain exercise tolerance.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash, urticaria or angioedema - Neuropsychiatric events including mood changes, depression or suicidal thoughts - Severe cutaneous adverse reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure patient safety. - Assess liver function: evaluate baseline hepatic enzymes in patients with liver disease. - Monitor for neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in pregnancy: limited data; weigh potential benefits against risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, affecting its plasma concentration or therapeutic effect.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition can increase montelukast exposure. - Phenobarbital: enzyme induction may markedly reduce montelukast levels. - Carbamazepine: hepatic enzyme induction may lower efficacy.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may raise montelukast concentrations. - Warfarin: potential alteration of INR; monitor coagulation parameters. - β‑agonists: additive bronchodilatory effect may increase risk of tachycardia.